Tag Archives: NASDAQ:ALXA

Healthcare Sector Summary: Alexza Pharmaceuticals (NASDAQ:ALXA), Metabolix (NASDAQ:MBLX) – ALXA, MBLX, SHLM, CADX, PGNX, RPRX

Posted on March 27, 2013 by Thomas Vedder

Investors reacted positively to the healthcare stocks on Tuesday. Major movement were observed in Cadence Pharmaceuticals, Inc (NASDAQ:CADX) and Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) on percentage gainers side while Repros Therapeutics Inc (NASDAQ:RPRX) was prominent stock on the losers side.

Alexza …

Posted in Healthcare, Latest Headlines | Tagged A. Schulman, Alexza Pharmaceuticals, ALXA, Cadence, CADX, MBLX, Metabolix, NASDAQ:ALXA, NASDAQ:CADX, NASDAQ:MBLX, NASDAQ:PGNX, NASDAQ:RPRX, NASDAQ:SHLM, PGNX, Progenics, Repros Therapeutics, RPRX, SHLM | Comments Off

Alexza Pharmaceuticals (NASDAQ:ALXA) Wins Approval for Adasuve by FDA – ALXA, SOMX, TSPT, XNPT

Posted on December 24, 2012 by Geoff Noir

Alexza Pharmaceuticals, Inc (NASDAQ:ALXA) reported on Saturday that the United States Food and Drug Administration approved its schizophrenia and bipolar disorder treatment Adasuve, one more latest win for the Mountain View, California based small drug manufacturer.

The medicine was approved …

Posted in Healthcare, Latest Headlines | Tagged Alexza Pharmaceuticals, ALXA, NASDAQ:ALXA, NASDAQ:SOMX, NASDAQ:TSPT, NASDAQ:XNPT, Somaxon, SOMX, Transcept, TSPT, XenoPort, XNPT | Comments Off

Pernix Therapeutics (NYSE:PTX) To Acquire Somaxon (SOMX); $25 Million Accord – PTX, CRME, DEPO, AGN, DVAX, AMRN, ALXA, PFE, JNJ

Posted on December 11, 2012 by Thomas Vedder

Pernix Therapeutics Holdings Inc (NYSE:PTX) reported on Tuesday that it is purchasing Somaxon Pharmaceuticals, Inc (NASDAQ:SOMX) in a stock-for-stock agreement, worth at $25 million.

The Woodlands, Texas based Pernix anticipates to benefit from Somaxon’s insomnia drug Silenor in the purchase, …

Posted in Healthcare, Latest Headlines | Tagged AGN, Alexza Pharmaceuticals, Allergan, ALXA, Amarin, AMRN, CARDIOME PHARMA, CRME, DEPO, Depomed, DVAX, Dynavax Technologies, JNJ, Johnson & Johnson, NASDAQ:ALXA, NASDAQ:AMRN, NASDAQ:CRME, NASDAQ:DEPO, NASDAQ:DVAX, NYSE:AGN, NYSE:JNJ, NYSE:PFE, NYSEAMEX:PTX, Pernix Therapeutics, PFE, Pfizer, PTX | Comments Off

Questcor Pharmaceuticals (NASDAQ:QCOR) Plans to Market Acthar; Stock Boosts – QCOR, SOMX, MYL, ALXA

Posted on June 16, 2012 by Geoff Noir

The Anaheim, California based Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) stock moved up on Friday after the corporation reported aims to promote its drug Acthar as a treatment for rheumatology conditions.

Questcor reported after the markets closed on Thursday that it would …

Posted in Healthcare, Latest Headlines | Tagged Alexza, ALXA, MYL, Mylan, NASDAQ:ALXA, NASDAQ:MYL, NASDAQ:QCOR, NASDAQ:SOMX, QCOR, Questcor, Somaxon, SOMX | Comments Off

Alexza (NASDAQ:ALXA) New Drug Application unaccepted, AMN (NYSE:AHS) Reports Results- ALXA, AHS, CFN, SQNM, HLF, LLY, BMY

Posted on May 7, 2012 by Geoff Noir

Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) announced on Friday its new drug application for Adasuve, a schizophrenic and bipolar disorder treatment, cannot be permitted by the US Food and Drug Administration until a deficiency at a manufacturing facility for the application is …

Posted in Healthcare, Latest Headlines | Tagged AHS, Alexza Pharmaceuticals, ALXA, AMN Healthcare Services, BMY, Bristol-Myers Squibb, CareFusion, CFN, Eli Lilly, Herbalife, HLF, LLY, NASDAQ:ALXA, NASDAQ:SQNM, NYSE:AHS, NYSE:BMY, NYSE:CFN, NYSE:HLF, NYSE:LLY, Sequenom, SQNM | Comments Off

Most Worse Momentum at Healthcare Sector, Shares Plunges More Than 20%- SGYP, ALXA, AMRN, WCRX, TEVA, RDEA, AGN

Posted on May 7, 2012 by Thomas Vedder

Shares of Synergy Pharmaceuticals (SGYP) go into the chasm, after the pharma’s reported that it plans to offer 10 million common stock shares to finance its research and development activities, which comprise clinical trials of its plecanatide and SP-333 treatments …

Posted in Healthcare, Latest Headlines | Tagged AGN, Alexza Pharmaceuticals, Allergan, ALXA, Amarin, AMRN, Ardea Biosciences, NASDAQ:ALXA, NASDAQ:AMRN, NASDAQ:RDEA, NASDAQ:SGYP, NASDAQ:TEVA, NASDAQ:WCRX, NYSE:AGN, RDEA, SGYP, Synergy Pharmaceuticals, TEVA, Teva Pharmaceutical, Warner Chilcott, WCRX | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.